

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)



(10) International Publication Number
WO 2021/249529 A1

(51) International Patent Classification:

C07C 13/465 (2006.01) A61P 1/16 (2006.01)
A61K 31/015 (2006.01) A61P 35/00 (2006.01)

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2021/099626

(22) International Filing Date:

11 June 2021 (11.06.2021)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/038,737 12 June 2020 (12.06.2020) US

(71) Applicant: NUCMITO PHARMACEUTICALS CO., LTD. [CN/CN]; 822 Liangting Road, Xiang'an, Xiamen, Fujian 361101 (CN).


(72) Inventors: SU, Ying; 822 Liangting Road, Xiang'an, Xiamen, Fujian 361101 (CN). ZHANG, Xiaokun; 822 Liangting Road, Xiang'an, Xiamen, Fujian 361101 (CN). CHEN, Ziwen; 822 Liangting Road, Xiang'an, Xiamen, Fujian 361101 (CN). CHEN, Qiangzhen; 822 Liangting Road, Xiang'an, Xiamen, Fujian 361101 (CN). WANG, Hais-han; 822 Liangting Road, Xiang'an, Xiamen, Fujian 361101 (CN). ZHANG, Xindao; 822 Liangting Road, Xiang'an, Xiamen, Fujian 361101 (CN). ZENG, Zhiping; 822 Liangting Road, Xiang'an, Xiamen, Fujian 361101 (CN). CAI, Li-jun; 822 Liangting Road, Xiang'an, Xiamen, Fujian 361101 (CN). ZHOU, Yuqi; 822 Liangting Road, Xiang'an, Xiamen, Fujian 361101 (CN).

(74) Agent: J.Z.M.C. PATENT AND TRADEMARK LAW OFFICE; YU, Mingwei, Room 5022, No. 335, Guo Ding Road, YANG Pu District, Shanghai 200433 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS



(57) Abstract: Provided herein are an indene compound, e.g., a compound of Formula (I), and a pharmaceutical composition thereof. Also provided herein is a method of their use for treating, preventing, or ameliorating one or more symptoms of a fibrotic disease.



WO 2021/249529 A1